

Deutsches Netzwerk gegen Antimikrobielle Resistenzen (DNAMR)

Deutscher Bundestag, Paul-Löbe-Haus


Parlamentarisches Frühstück

18. Januar 2024

Resistenzsituation & Antibiotikaverbrauch in Deutschland

Michael Kresken

Leiter der AG Empfindlichkeitsprüfungen & Resistenz
Paul-Ehrlich-Gesellschaft für Infektionstherapie e. V.




Einsatzgebiete von Antibiotika




Antibiotikaeinsatz in Deutschland, 1991-2022

- Apothekenmarkt (Packungen) -




Antibiotikaverbrauch in Deutschland, 1991-2022


Krankenhausmarkt (Zähleinheiten, ZE)



Resistenzentwicklung bei *E. coli* PEG-Daten, 1975-2019 – Hospitalbereich




Resistenzentwicklung bei E. coli PEG-Daten, 1975-2019 – Hospitalbereich




Korrelation

Antibiotikaverbrauch – Antibiotikaresistenz




Note: Average antibiotic resistance is from EARS-Net database of the European Centre for Disease Prevention
Antibiotic usage is from the European Surveillance of Antimicrobial Consumption (ESAC) Yearbook 2009

Häufigkeit Carbapenem-resistenter Gram-negativer Erreger* in D, F, I und GR – EARS-Net-Daten, 2022



*CRAB = Carbapenem-resistente *Acinetobacter* spp.;
CRPA = Carbapenem-resistente *P. aeruginosa*;
CRKP = Carbapenem-resistente *K. pneumoniae*

Anteil von Carbapenem-resistenten Stämmen an invasiven *K. pneumoniae*-Isolaten (ResistanceMap – One Health Trust*)



In-vitro-Aktivität von „Reserveantibiotika“ gegen Carbapenem-resistente Gram-negative Erreger

	<i>Enterobacterales</i>				<i>P. aeruginosa</i>		<i>Acinetobacter</i>	<i>Stenotrophomonas</i>
	KPC+	OXA-48-like+	MBL+	CP-	MBL+	CP-		
Imipenem/Relebactam*	●	●	●	●	●	●	●	●
Meropenem/Vaborbactam	●	●	●	●	●	●	●	●
Ceftazidim/Avibactam*	●	●	●	●	●	●	●	●
Ceftolozan/Tazobactam*	●	●	●	●	●	●	●	●
Eravacyclin	●	●	●	●	●	●	●	●
Plazomicin	●	●	●	●	●	●	●	●
Cefiderocol*	●	●	●	●	●	●	●	●
Colistin	●	-	●	●	●	●	●	●

● > 80% ● 50 - 80% ● < 50%

*vom G-BA als Reserveantibiotikum eingestuft



